LXEO – lexeo therapeutics, inc. (US:NASDAQ)

News

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.
Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $19.00 price target on the stock.
Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at Wall Street
Lexeo Therapeutics: Behind The Rebound [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com